Pancreatic Cell News 7.42 October 25, 2016 | |
| |
TOP STORYGold Nanoparticle Reprograms Pancreatic Tumor Microenvironment and Inhibits Tumor Growth The authors demonstrated that gold nanoparticles inhibited proliferation and migration of both pancreatic cancer cells and pancreatic stellate cells by disrupting the bidirectional communication via alteration of the cell secretome. [ACS Nano] Abstract | Press Release | |
| |
PUBLICATIONS(Ranked by impact factor of the journal)DIABETES & PANCREATITISScientists provide evidence that during onset of islet autoimmunity, the insulin-specific target T-cell population is enriched with a C-X-C chemokine receptor type 5 (CXCR5)+CD4+ TFH precursor phenotype. [Proc Natl Acad Sci USA] Abstract | Press Release Recombinant Reg3β Protein Protects Against Streptozotocin-Induced β-Cell Damage and Diabetes Researchers produced a recombinant Reg3β protein and provided evidence that it is active in promoting islet β-cell survival against streptozotocin-triggered cell death. [Sci Rep] Full Article To analyze control of cellular energy metabolism in adherent cell cultures of the INS-1832/13 pancreatic β-cell model investigators adapted their microscopy assay of absolute mitochondrial membrane potential to a fluorescence microplate reader format, and applied it in conjunction with cell respirometry. [Biochim Biophys Acta] Abstract NF-κB has an essential role in the initiation and progression of pancreatic cancer and specifically mediates the induction of epithelial–mesenchymal transition and invasiveness. Researchers demonstrated the importance of activated NF-κB signaling in epithelial–mesenchymal transition induction, lymphovascular metastasis, and neural invasion. [Lab Invest] Abstract Ciclopirox Enhances Pancreatic Islet Health by Modulating the Unfolded Protein Response in Diabetes The authors explored the antidiabetic activity of ciclopirox (CPX), an iron chelator and recently described activator of p21 expression. The effects of CPX in beta cell survival and function were assessed in cultured islets in vitro as well as in diabetic mice in vivo. [Pflugers Arch] Abstract Scientists tested whether exposure of beta cells at reduced glucose leads to mitochondrial adaptions and whether such adaptions modulate effects of hypoxia. [Islets] Abstract PANCREATIC CANCERA new type of tumor-targeted nanovehicle peptide-conjugated PSPG was successfully synthesized for co-delivery of paclitaxel (PTX) and TR3 small interfering RNA (siRNA). [Small] Abstract | Graphical Abstract Desmoplasia Suppression by Metformin-Mediated AMPK Activation Inhibits Pancreatic Cancer Progression The authors first evaluated the expression of AMP-activated protein kinase (AMPK) and phosphorylated-AMPK in normal and pancreatic ductal adenocarcinoma (PDAC) tissues. They then determined the efficacy of metformin on PDAC growth in vitro and in vivo. [Cancer Lett] Abstract Investigators report that HMNE3, a novel bis-fluoroquinolone chalcone-like derivative that targets both tyrosine kinase and topoisomerase II, induces tumor cell proliferation and growth inhibition. [PLoS One] Full Article | |
| |
REVIEWSThe authors give a description of the different types of putative endothelial progenitor cells studied and describe the mechanism promoting a reduction in their number and function in diabetes and the pathological consequences. [Pharmacol Ther] Abstract Visit our reviews page to see a complete list of reviews in the pancreatic cell research field. | |
| |
SCIENCE NEWSMauna Kea Technologies announced positive results from the CONTACT clinical study on the characterization of pancreatic cysts using Cellvizio® confocal laser endomicroscopy. [Press release from Mauna Kea Technologies discussing research presented at United European Gastroenterology Week, Vienna] Press Release | |
| |
INDUSTRY NEWSUC San Diego School of Medicine Researchers Receive $5 Million in Type 1 Diabetes Grants Researchers at University of California San Diego School of Medicine hope to answer some of the unanswered questions about the mechanisms that contribute to the onset of type 1 diabetes with two Type 1 Diabetes Special Statutory Funding Program grants from the National Institutes of Health totaling more than $5 million. [UC San Diego] Press Release Lexicon Pharmaceuticals, Inc. announced that the Phase II dose-ranging, inTandem4 clinical trial of dual SGLT1 and SGLT2 inhibitor sotagliflozin met its primary endpoint, showing a statistically significant reduction in A1C at 12 weeks in patients with type 1 diabetes. [Lexicon Pharmaceuticals, Inc.] Press Release Relief Therapeutics Holding AG announced a strategic collaboration agreement between its subsidiary Relief Therapeutics SA and FirstString Research Inc. for the support of the clinical development in the United States of atexakin alfa, a low-dose formulation of recombinant human interleukin 6. [Relief Therapeutics Holding AG] Press Release OncoQuest Inc. announced positive results from its pre-clinical pharmacology studies using its Anti-MUC1 antibody, MAb AR20.5, against pancreatic cancer in a human MUC1 expressing transgenic mouse model. [Quest PharmaTech Inc.] Press Release Atrin Pharmaceuticals, Inc. announced receipt of a Phase I Small Business Technology Transfer Award for approximately $300,000 from the National Cancer Institute of the National Institutes of Health. The award supports Atrin’s development of highly specific inhibitors of ATR for the targeted treatment of a broad spectrum of cancers. [Atrin Pharmaceuticals, Inc. (PR Newswire Association LLC.)] Press Release The National Institutes of Health has awarded two co-investigators at Albert Einstein College of Medicine a five-year, $2.6 million grant to make immunotherapy agents that more precisely and effectively treat a variety of cancers while causing far fewer side effects than current immunotherapies. [Albert Einstein College of Medicine] Press Release | |
| |
POLICY NEWSReview Finds Misconduct in Events Surrounding WHO Fetal Growth Study For the first time in its 68-year history, the World Health Organization (WHO) has concluded that researchers are guilty of research misconduct. An independent review commissioned by WHO has found that “research ethics misconduct occurred” in a multimillion-dollar global study on fetal growth led by researchers at the University of Oxford in the United Kingdom. [ScienceInsider] Editorial Two Major California Research Institutes Will Merge One of the biggest nonprofit biomedical research outfits in the world is getting a new translational medicine research arm, aimed at speeding the conversion of basic research insights into novel medicines. Officials at the Scripps Research Institute announced that it will merge with the California Institute for Biomedical Research, which was launched in 2012 as a nonprofit version of a drug development company. [ScienceInsider] Editorial To Save Money, NSF Requires University Cost-Sharing for Rotators The National Science Foundation (NSF) has decided that universities should pay 10% of the salaries of faculty members working temporarily at the agency. NSF hopes the new policy will demonstrate its commitment to saving taxpayer dollars without alienating the academic community that it relies upon to stay on the cutting edge of basic science. [ScienceInsider] Editorial
| |
EVENTSNEW 29th Lorne Cancer Conference Visit our events page to see a complete list of events in the community.
| |
JOB OPPORTUNITIESNEW Postdoctoral Researcher – Type II Diabetes and Islet Biology (Lund University) NEW Research Associate – Cancer Therapeutics (Cancer Research UK Cambridge Institute) Postdoctoral Fellow – Cancer and Immunometabolism (The University of Michigan) Postdoctoral Researcher – Pancreatic Cancer (Van Andel Research Institute)>) Postdoctoral Fellowship – Pancreatic Cancer (University of Liège) Postdoctoral Position – Immunology of Diabetes (INSERM) Vice President – Pancreatic Cancer Disease Lead (Celgene Corporation) Postdoctoral Research Fellow – Pancreas Cancer (Fred Hutchinson Cancer Research Center) Chair of Medical Biology (Masaryk University) Postdoctoral Position – Cancer Research (Sanford Burnham Prebys Medical Discovery Institute) Assistant Scientist – Diabetes Research (University of Miami) Postdoctoral Fellow – Pancreatic Stem Cell Biology (University of Southern California) Recruit Top Talent: Reach potential candidates by posting your organization’s career opportunities on the Connexon Creative Job Board at no cost.
| |
Have we missed an important article or publication in Pancreatic Cell News? Click here to submit! Comments or suggestions? Submit your feedback here. | |
|
Home Pancreatic Cell News Volume 7.42 | Oct 25 2016